Drugs / Tegafur/Uracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00519688 | Jul 2006 → Aug 2010 | hepatocellular carcinoma | National Taiwan University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegafur/Uracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00519688 ↗ |
| Action | Inhibit | “Uracil is an inhibitor of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme of 5-FU degradation.” NCT00519688 ↗ |
| Route | Oral | “Both drugs are orally active” NCT00519688 ↗ |